Clinical Utility of KAP-1 Expression in Thyroid Lesions
- 220 Downloads
Although there are evidences of the involvement of KAP-1 in other tumors, data on differentiated thyroid carcinomas (DTC) are still lacking. We aimed to evaluate KAP-1 clinical utility in the diagnosis and prognosis of DTC. We used both visual immunohistochemistry and a semiquantitative analysis to evaluate KAP-1 expression in 230 thyroid carcinomas and 131 noncancerous thyroid nodules. There were 43 follicular carcinomas (FC) and 187 papillary thyroid carcinomas (PTC), including 130 classic (CPTC), 4 tall cells (TCPTC), and 53 follicular variants (FVPTC). Patients were followed up for 53.8 ± 41 months. They were classified as free-of-disease (142 cases) or poor outcome (25 cases—10 deaths), according to their serum Tg levels and image evidences. KAP-1 was identified in 78 % PTC, 75 % TCPTC, 74 % FC, 72 % FVPTC, 55 % FA, 44 % hyperplasia, and 11 % normal thyroid tissues. A ROC analysis identified malignant nodules with 69 % sensitivity and 75 % specificity, using a cutoff of 73.19. In addition to distinguishing benign from malignant thyroid tissues (p < 0.0001), KAP-1 expression differentiated CPTC from nodular hyperplasia (p < 0.0001), CPTC from FA (p = 0.0028), FVPTC from hyperplasia (p = 0.0039), and FC from hyperplasia (p = 0.0025). Furthermore, KAP-1 was more expressed in larger tumors (>4 cm; p = 0.0038) and in individuals who presented recurrences/metastases (p = 0.0130). We suggest that KAP-1 may help diagnose thyroid nodules, characterize follicular-patterned thyroid lesions, and identify individuals with poor prognosis.
KeywordsKAP-1 Thyroid nodule Follicular thyroid lesions Outcome
We thank the State of São Paulo Research Foundation (Fapesp) for supporting this study.
- 2.Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD, Jr., Kim BW, Nose V, Marqusee E, Larsen PR, Alexander EK (2007) Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 111 (6):508–516. doi: 10.1002/cncr.23116 PubMedCrossRefGoogle Scholar
- 3.Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, Zeiger MA, Westra WH, Wang Y, Khanafshar E, Fellegara G, Rosai J, Livolsi V, Lanman RB (2011) A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid 21 (3):243–251. doi: 10.1089/thy.2010.0243 PubMedCrossRefGoogle Scholar
- 6.SEER (2012) Cancer Statistics Review 1975–2009. http://seer.cancer.gov/csr/1975_2009_pops09. Accessed 23 June 2012
- 9.Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR (2012) Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367 (8):705–715. doi: 10.1056/NEJMoa1203208 PubMedCrossRefGoogle Scholar
- 15.Cammas F, Herzog M, Lerouge T, Chambon P, Losson R (2004) Association of the transcriptional corepressor TIF1beta with heterochromatin protein 1 (HP1): an essential role for progression through differentiation. Genes Dev 18 (17):2147–2160. doi: 10.1101/gad.30290418/17/2147 PubMedCrossRefGoogle Scholar
- 19.Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 (8):816–824. doi: 10.1038/nm733nm733 PubMedGoogle Scholar
- 21.Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19 (11):1167–1214. doi: 10.1089/thy.2009.0110 PubMedCrossRefGoogle Scholar
- 22.Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, Soares FA, Vassallo J, Ward LS (2012) Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 77 (6):918–925. doi: 10.1111/j.1365-2265.2012.04482.x CrossRefGoogle Scholar
- 23.Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, Soares FA, Vassallo J, Ward LS (2012) Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer. Endocr Relat Cancer 19 (3):L31-36. doi: 10.1530/ERC-11-0285 PubMedCrossRefGoogle Scholar
- 29.Hirsch D, Ginat M, Levy S, Benbassat C, Weinstein R, Tsvetov G, Singer J, Shraga-Slutzky I, Grozinski-Glasberg S, Mansiterski Y, Shimon I,t Reicher-Atir R (2009) Illness perception in patients with differentiated epithelial cell thyroid cancer. Thyroid 19 (5):459–465. doi: 10.1089/thy.2008.0360 PubMedCrossRefGoogle Scholar